Actigraphy Improvement With Voxelotor (ActIVe) Study

Pfizer

Status and phase

Completed

Phase 4

Conditions

Sickle Cell Anemia

Sickle Cell Disease

Treatments

Drug: Voxelotor

Study type

Interventional

Funder types

Industry

Identifiers

NCT04400487

GBT440-039

C5341024 (Other Identifier)

Details and patient eligibility

About

This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.

Full description

All participants will receive Voxelotor as treatment. There will be approximately 13 sites in the US.

Participant safety and tolerability will be monitored during the study using standard measures, including physical examinations, vital signs (including temperature, blood pressure, pulse rate, respiratory rate and peripheral oxygen saturation [SpO2]), clinical laboratory tests, and adverse event (AE) monitoring.

Screening Period (up to 4 weeks in duration): During this period, participants will sign the informed consent form (ICF), after which they will complete the screening assessments as detailed in the Schedule of Assessments (SOA).

Run-in Period (2 weeks in duration): During this period, participants will enter a 2-week run-in period (Day -14 to Day -1) during which baseline actigraphy measures of physical activity and sleep quality, overnight pulse oximetry assessments of oxygen saturation, and Patient-Reported Outcome (PRO) assessments will be collected before initiating treatment with voxelotor.

Treatment Period (24 weeks in duration): After completion of the 14-day Run-in Period, participants will enter the open label treatment period and receive voxelotor 1500 mg once daily for 24 weeks. Repeat actigraphy assessments of physical activity and sleep quality, and overnight pulse oximetry will be performed during the treatment period (Weeks 10 to 12 and Weeks 22 to 24). PRO and Clinical Global Impression (CGI) assessments will be completed at scheduled study visits. The open-label treatment period is considered the continuous 24 weeks of voxelotor treatment from date of first dose (Day 1).

Follow-up Period (4 weeks in duration): Immediately following the 24-week treatment period, participants will enter a 4-week Follow-up Period.

Enrollment

25 patients

Sex

All

Ages

12 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female participants with SCA (sickle hemoglobin with two sickle cell genes [HbSS] or sickle hemoglobin (S) and one beta thalassemia gene [HbS β0] thal genotype)
Between 12 to 55 years of age (inclusive)
Screening Hb level ≤8.0 g/dL
Treatment with hydroxyurea (HU) therapy on study is permitted if the participant has been on a stable dose for at least 90 days before enrollment with no dose modifications planned or anticipated by the Investigator
Treatment with glutamine is permitted
Treatment with erythropoiesis-stimulating agents (ESAs) is permitted if the participant has been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator
Female participants of child-bearing potential must use highly effective methods of contraception to 30 days after the last dose of study drug. Male participants must use barrier methods of contraception to 30 days after the last dose of study drug
Females of child-bearing potential are required to have a negative pregnancy test before the administration of study drug
Written informed consent and/or parental/guardian consent and participant assent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines

Exclusion criteria

Red blood cell (RBC transfusion within 3 months before initiation of study drug
Planned initiation of regularly scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) during the study
Hospitalization for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 30 days prior to informed consent/assent.
More than 10 VOCs requiring hospitalization, emergency department or clinic visit within the past 12 months
Planned elective surgery within the next 6 months
Physical inactivity attributable to clinically significant musculoskeletal, cardiovascular, or respiratory comorbidities
Anemia due to bone marrow failure (eg, myelodysplasia)
Absolute reticulocyte count (ARC) < 100 x10^9/L
Screening alanine aminotransferase (ALT) > 4× upper limit of normal (ULN)
Severe renal dysfunction (estimated glomerular filtration rate [GFR] < 30 mL/min/1.73 m2 by Schwartz formula) or is on chronic dialysis
Known active hepatitis A, B or C or known to be human immunodeficiency virus (HIV)-positive.
Females who are breast-feeding or pregnant
Major surgery within 8 weeks before enrollment. Participants must have completely recovered from any previous surgery before enrollment
History of hematopoietic stem cell transplant or gene therapy
Received an investigational drug within 30 days or 5-half-lives, whichever is longer, prior to consent, or is currently participating in another trial of an investigational or marketed drug (or medical device)
Use of concomitant medications (eg, crizanlizumab) that confound the ability to interpret data from the study
Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or, render the participant unable/unlikely to comply with the study procedures
Use of herbal medications (e.g., St. John's Wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or moderate or strong CYP3A4 inducers
Symptomatic coronavirus disease of 2019 (COVID-19) infection